Clinical trial • Phase III • Oncology

Clinical trial in Monoclonal gammopathy of renal significance (MGRS)

Phase III trial for Monoclonal gammopathy of renal significance (MGRS). 30 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Monoclonal gammopathy of renal significance (MGRS)
Trial Stage
Phase III

Key dates

Initial CTIS Submission Date
20-12-2024
First CTIS Authorization Date
29-01-2025

Trial design

Phase III trial across 1 site in Finland.

Target Sample Size
30

Eligibility

Recruits 30 Vulnerable population not selected (isVulnerablePopulationSelected: false); no special consent or assent procedures are described in the record..

Vulnerable Population
Vulnerable population not selected (isVulnerablePopulationSelected: false); no special consent or assent procedures are described in the record.

Recruitment

Planned Sample Size
30
Recruitment Window Months
34

Geography

Total Number Of Sites
1
Total Number Of Participants
30

Finland

Earliest CTIS Part Ii Submission Date
20-12-2024
Latest Decision Or Authorization Date
29-04-2026
Processing Time Days
495
Number Of Sites
1
Number Of Participants
30

Sites

Site Name
HUS-Yhtymae
Department Name
Nephrology
Principal Investigator Name
Kati Kaartinen
Principal Investigator Email
kati.kaartinen@hus.fi
Contact Person Name
Kati Kaartinen
Contact Person Email
kati.kaartinen@hus.fi
Number Of Participants
30

Sponsor

Primary sponsor

Full Name
HUS-Yhtymae
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Finland

Related trials

Other published trials that may interest you.